Thursday, September 28, 2023

Hemp Stock News: Hempacco (NASDAQ: HPCO) and Snoop Dogg Collaborate to Launch 'Dogg lbs' Gummies with AI-Created Artwork

Hemp Stock News: Hempacco (NASDAQ: HPCO) and Snoop Dogg Collaborate to Launch 'Dogg lbs' Gummies with AI-Created Artwork: Hemp Stock News: Hempacco (NASDAQ: HPCO) and Snoop Dogg Collaborate to Launch 'Dogg lbs' Gummies with AI-Created Artwork

Cannabis Stock News: Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) Announces C$34 Million Bought Deal Financing Intends to Repay Remaining Convertible Debt Balance

Cannabis Stock News: Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) Announces C$34 Million Bought Deal Financing Intends to Repay Remaining Convertible Debt Balance: Cannabis Stock News: Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) Announces C$34 Million Bought Deal Financing Intends to Repay Remaining Convertible Debt Balance

Cannabis Stock News: Seattle's Jones Soda (CSE: JSDA, OTCQB: JSDA) Brings Cannabis Brand Mary Jones to Washington State

Cannabis Stock News: Seattle's Jones Soda (CSE: JSDA, OTCQB: JSDA) Brings Cannabis Brand Mary Jones to Washington State: Cannabis Stock News: Seattle's Jones Soda (CSE: JSDA, OTCQB: JSDA) Brings Cannabis Brand Mary Jones to Washington State

Friday, September 15, 2023

New #InvestorIdeas (TSXV: $ONYX.V) (TSXV: $CAM.V) (NYSE: $TTE) (NYSE: $SRFM) (CSE: $MESC.C) (Nasdaq: $ODD)

 New #InvestorIdeas (TSXV: $ONYX.V) (TSXV: $CAM.V) (NYSE: $TTE) (NYSE: $SRFM) (CSE: $MESC.C) (Nasdaq: $ODD)

 

New #Stocks to watch in #Mining, #Green/ #EcoFriendly, #Psychedelics and #Tech

 



 

 

September 15, 2023 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Mining, Green/Eco-Friendly, Psychedelics and Tech. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2023/main/09151Stocks.asp

 

The newest mining companies are both operating in Canada and focussed on gold/copper.

 

The latest green companies are involved in biofuels/natural gas and electrified aircraft, respectively.

 

The newest psychedelic company is working with peyote cactus, and the latest tech company is focussed on the use of AI in the health/wellness and beauty sectors.

 

New Stocks Added to the Mining Directories:

Onyx Gold Corp. (TSXV:ONYX) is an exploration company focused on well-established Canadian mining jurisdictions, with assets in Timmins, Ontario and Yukon Territory. The Company's extensive portfolio of quality gold projects in the greater Timmins gold camp includes the Munro-Croesus Gold property, renowned for its high-grade mineralization, plus two additional earlier-stage large exploration properties, Golden Mile and Timmins South. Onyx Gold also controls four properties in Selwyn Basin area of Yukon Territory, which is currently gaining significance due to recent discoveries in the area. Onyx Gold's experienced board and senior management team are committed to creating shareholder value through the discovery process, careful allocation of capital, and environmentally/socially responsible mineral exploration.

 

Cascadia Minerals Ltd. (TSXV:CAM) is a Canadian junior mining company focused on exploring for copper and gold in Yukon and British Columbia. Cascadia's flagship Catch Property is a brand-new grassroots discovery which exhibits extensive high-grade copper and gold mineralization across a 5 km long trend, with rock samples returning peak values of 3.88% copper and 30.00 g/t gold. The maiden diamond drill program at Catch is underway. In addition to Catch, Cascadia is conducting exploration work at its PIL Property in British Columbia and the Sands of Time and Rosy properties in Yukon, as well as evaluating additional regional opportunities.

 

New stocks added to the Green/Eco-Friendly Directory:

TotalEnergies SE (NYSE:TTE) is a global multi-energy company that produces and markets energies: oil and biofuels, natural gas and green gases, renewables and electricity. Our more than 100,000 employees are committed to energy that is ever more affordable, cleaner, more reliable and accessible to as many people as possible. Active in nearly 130 countries, TotalEnergies puts sustainable development in all its dimensions at the heart of its projects and operations to contribute to the well-being of people.

 

SURF AIR MOBILITY INC. (NYSE: SRFM) is a Los Angeles-based regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of flying and as the operator of the largest commuter airline in the US, Surf Air Mobility intends to develop powertrain technology with its commercial partners to electrify existing fleets and bring electrified aircraft to market at scale. The management team has deep experience and expertise across aviation, electrification, and consumer technology.

 

New Stocks added to the Psychedelics Directory:

Lophos Holdings Inc. (CSE:MESC) pertains to the cultivation and research of Lophophora williamsii (“peyote cactus”). Additionally, in the long-term, the Company is engaged in the research and development of compounds derived from peyote cactus. The company’s wholly-owned subsidiary, Lophos Pharmaceuticals Corp., is a biosciences company that specializes in peyote cactus cultivation, research, and sale. It is also licensed to possess, produce, sell/provide, send, transport and deliver the controlled substances covered by its Controlled Substances Dealers License (CSDL), namely mescaline, psilocin and psilocybin.

 

New Stocks added to the Tech Directory:

Oddity Tech Ltd (Nasdaq:ODD) is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company owns IL MAKIAGE and SpoiledChild brands. ODDITY, which operates with business headquarters in New York City, R&D center in Tel Aviv, and biotechnology lab in Boston, has built one of the industry's most advanced AI-driven online platforms, leveraging data science, machine learning and computer vision capabilities to deliver a better online experience for consumers. The company deploys cutting-edge data science to identify consumer needs and develops solutions in the form of beauty, wellness, and tech products. ODDITY operates ODDITY LABS, an industry leading biotechnology center and pioneer in artificial intelligence-based molecule discovery. ODDITY LABS develops a wide range of proprietary ingredients, including novel molecules, probiotics, and peptides, for the advancement of high performing, science-backed, and beauty and wellness products that address a broad spectrum of consumer needs.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp Disclosure: AppTech Payments Corp. (NasdaqCM:APCX) is a paid featured Fintech company on Investorideas.com.

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800 665 0411 

 


Thursday, September 7, 2023

Cannabis Stock News: Aurora (NASDAQ: ACB) (TSX: ACB) Expands Strains for Heroes Offerings Designed for Veterans, by Veterans

Cannabis Stock News: Aurora (NASDAQ: ACB) (TSX: ACB) Expands Strains for Heroes Offerings Designed for Veterans, by Veterans: Cannabis Stock News: Aurora (NASDAQ: ACB) (TSX: ACB) Expands Strains for Heroes Offerings Designed for Veterans, by Veterans

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move: (OTCQX: $CURLF), (NASDAQ: $ACB) and (OTC: $HEMP)

 



 

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move: (OTCQX: $CURLF), (NASDAQ: $ACB) and (OTC: $HEMP)

 

September 7th, 2023 (Investorideas.com Newswire), investorideas.com,  a global news source covering leading sectors including marijuana and hemp stocks and its potcast site  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2023/090723-Cannabis.mp3

 

Read this in full at https://www.investorideas.com/news/2023/cannabis-potcasts/09071CURLF-ACB-HEMP.asp

In today’s podcast we go over a few public company announcements, the potential policy changes around recreational cannabis use for the RCMP, a new study which suggests cannabis legalisation has led to an increase in cannabis-involved traffic injury emergency department visits and the continued rise of cannabis stocks on the speculation of cannabis rescheduling in the U.S.

 

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLFannounced the launch of Zero Proof, a new brand of THC drinkables in fast-acting, sessionable and easy-to-use formats. The brand's inaugural product offering, Squeeze, is now available at all Curaleaf locations in Illinois and will be followed by additional SKUs in the coming months.

 

Zero Proof Squeeze follows Select's popular THC-infused beverage enhancer, Select Squeeze, originally launched in March 2021. While similar in functionality and effect, Zero Proof Squeeze has been reformulated with natural sweetener to provide a significantly lighter taste and balanced flavour profile for enhanced mixability. The beverage complement offers a uniquely controllable and customizable experience with an easy-to-pour dispenser and compact design delivering 2.5mg THC per dose for discreet enjoyment on the go.

 

Utilising nanotechnology, Zero Proof Squeeze provides a truer-to-flower experience with effects felt in as little as 15-30 minutes, significantly faster than traditional edibles. By turning cannabis oil into tiny water-soluble molecules, the THC compounds dissolve evenly into any beverage and are more rapidly and efficiently absorbed into the bloodstream. At launch, four delicious, low calorie and gluten-free flavours will be available including Dash of Cherry, Dash of Orange, Dash of Lime and Dash of Sweet.

 

"Zero Proof exemplifies our commitment to providing high-quality, consistent consumer products in familiar and approachable formats that model traditional consumer packaged goods," said Matt Darin, CEO of Curaleaf. "Curaleaf has been on the forefront of creating sophisticated cannabis experiences which we believe will ultimately redefine the way people socialise. We're proud to bring Zero Proof Squeeze to our patients and customers in Illinois first before expanding to additional markets."

 

According to a new Gallup poll, the rate of alcohol consumption in the U.S. continues to decline with 62% of adults under age 35 reporting they drink alcohol, down 10% from two decades ago. Zero Proof is the latest addition to Curaleaf's brand portfolio that seeks to redefine how people socialise by delivering a fast-acting, sessionable alternative to alcohol.

 

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), announced an expansion of its hemp-derived CBD portfolio into Brazil. In partnership with Herbarium, the leading Brazilian full-spectrum, single-source 3% CBD oil, under the Herbarium brand. Now available under the direction of medical doctors, patients across Brazil have access to high quality CBD as part of their healthcare.

 

"We are proud to continue our international expansion and bring quality CBD products to Brazilians alongside our partner, Herbarium, a trusted brand in the market," says Andre Jerome, EVP of Global Business Development at Aurora Cannabis. "Brazil has strong growth potential, and we look forward to leveraging our leadership in the market to further unlock key opportunities in South America."

 

The CBD oil is produced at Aurora's production facility in Uruguay, one of the only GMP-certified cannabis processing facilities in the country. Known for quality and reliability, Aurora is a leading global supplier of a complete portfolio of cannabis products, including CBD offerings, to 13 countries internationally.company in herbal medicine, Aurora will launch the company's

 

Hemp, Inc. (OTC:HEMPhas been cited as one of the key players as the future scope of industrial hemp is set to reach $18.6 billion by 2027.

 

According to the latest report (published September 1, 2023) Industrial Hemp Market Industry Increasing Demand, Emerging Trends, Growth, and Future Scope by 2027 provides a quantitative analysis of market segments and current trends, and Hemp, Inc. is profiled as one of the key players driving the market. 

 

The industrial hemp industry is a rapid, eco-conscious marvel and according to one common denominator of recent reports, hemp-based products will continue to have significant growth over the next few years which will undoubtedly bring more opportunities to companies well-positioned in the industry.

 

Hemp, Inc.’s e-portal (www.hempinc.com) to its CBD products is primed and poised to capture a large share of the marketplace, not just domestically but globally if the hemp industry continues to evolve at this rate.  Report after report, as another one mentioned in a previous press release, is seeing a surge in the “younger population toward organic and natural products' ' which is anticipated to drive the demand for hemp-based products globally. There’s no doubt Hemp, Inc. has a superb lineup of CBD/CBG/CBN products so the Company is well-positioned to grab a sizable portion of that market share. Hemp, Inc.’s products include a CBD-CBG Topical Pain Relief Roll-on (THC-free with 1,460mg of CBD and 630mg of CBG totaling 2,090mg of cannabinoids in 5ml), CBD/CBG Natural Coffee Enhancers, CBD/CBG Tinctures, and, CBDa/CBGa/CBD/CBG/CBN Capsules.

 

The Company also discovered its grounded kenaf hemp blend makes the perfect substrate to grow healthy and/or medicinal mushrooms and has the capability to make and/or provide the raw materials to produce hemp-based products such as hempcrete, horse bedding, hemp bioplastics, and more. Needless to say, Hemp, Inc. continues to have a strong foothold in the market with an invaluable roster of manufacturers and vendors across the country and abroad to see meteoric growth curves on a domestic and international scale.

 

“Industrial hemp or hemp is a variety of Cannabis sativa plant species that is grown especially for commercial purposes. Industrial hemp is a fast-growing, environmentally friendly plant with a low cost to produce. It is also one of the multipurpose and sustainable crops in the world. Moreover, industrial hemp can be refined into a variety of commercial items such as rope, paper, clothing, textiles, insulation, paint, biodegradable plastics, food, biofuel, and animal feed.” (Source)

 

In recent news, the RCMP has suggested easing a policy that requires front-line officers and many other employees to refrain from recreational cannabis use for four weeks before duty.

 

A change to the five-year-old policy could bolster recruitment of new officers by bringing the Mounties in line with police forces that have much less restrictive policies on pot use

 

An internal RCMP briefing note, obtained by The Canadian Press through the Access to Information Act, recommends a 24-hour restriction on cannabis use before reporting to work, with some exceptions.

 

RCMP spokeswoman Robin Percival says the current policy is under review but no final decision has been made.

 

The policy took effect in 2018 when Canada legalised recreational cannabis.

 

It requires RCMP employees in safety-sensitive positions to refrain from non-medicinal

cannabis use 28 days before reporting to work.

 

The policy covers a wide array of employees, from officers and reservists to telecommunication operators and firearm technicians.

 

The RCMP says it reviewed all aspects of its operations in developing the 2018 policy on substance use. It reasoned that members work across Canada in a unique environment, including as first responders, in rural and remote communities and can be called back for duty at any time.

 

“All RCMP employees must be fit for duty when reporting for work, which includes not being impaired by alcohol or drugs,” says a notice on the RCMP website explaining the policy.

“Science shows that cannabis can intoxicate beyond initial consumption and that there are no established safe limits or data on how it affects performance. Without established scientific information about cannabis impairment, the RCMP policy is taking a careful approach at this time, to ensure workplace and public safety is maintained at all times.”

 

In other newsaccording to a new study, which I highly recommend you read in full detail to determine the veracity of the study, suggests that over a span of 11 years, annual rates of Ontario emergency department visits for cannabis-related traffic injuries surged dramatically.

The study, published Wednesday in JAMA Network Open, looked at cannabis involvement in emergency room visits for traffic injuries between 2010 and 2021 in Ontario. It also examined shifts in cannabis consumption and driving habits following federal legalisation in 2018.

 

“Our data is raising concern about a growing problem of cannabis impairment and severe road injuries,” said lead author, Dr. Daniel Myran, who is also a fellow at the Bruy√®re Research Institute and with the University of Ottawa’s Department of Family Medicine.

“Since 2010 there has been a very, very large increase in cannabis involvement and traffic injury visits in Ontario.”

 

When the study is looked at under closer examination we do see that there is no data on which percentage of the 7564 alcohol related traffic injury ED visits and the 426 cannabis related traffic injury ED visits had any crossover. One of the issues when looking at cannabis as an impairment for driving, or in any testing situation, is the fact that cannabis remains in the blood for up to 90 days. This is an issue I have discussed often on the podcast and one which is well known in the cannabis testing world.

Another issue which has come up often when such statistics surrounding cannabis are brought up in the media or in studies is we often intentionally omit the fact that many of these cannabis related traffic injuries, also have alcohol in their system, and that it is actually the alcohol which leads to further coordination and reflex impairment.

 

A hypothetical scenario, which has occurred many times in such data sets, is someone who gets in a drunk driving accident also still has high levels of THC in their system from consumption that is sometimes days previous to the accident. The report is then filed twice, once as a cannabis incident and once again as an alcohol related incident. There has also been occasion where it is only cited as a cannabis related incident.

 

Again to any interested in the data provided by this study, I suggest a thorough read.

 

Finally, we continue to see Cannabis stocks, including Canopy Growth (CGC), Curaleaf Holdings (CURLF), and Leafly Holdings (LFLY) to name but a few, got a boost in trading after media reports, as well as a Marijuana Moment report stated that President Biden has been “very clear” about the “the legalisation of marijuana for medical purposes.”

 

This is all based on the news surrounding the HHS recommending a “rescheduling” of cannabis from a Schedule I drug to a Schedule III status which we covered in our previous podcast.

 

While this speculation is currently a boon for the investment side of the industry, investors and supporters of cannabis should be cautious of becoming overly optimistic given the many times in the past there has been speculation surrounding the SAFE banking act and cannabis decriminalisation which did not materialise. The fact that the Biden administration has come under heavy criticism for not acting enough when it comes to cannabis regulations and is heading into an election year should also be taken into consideration.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

 

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) ,  Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio ,  Google Podcasts and most audio platforms available.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Tuesday, September 5, 2023

Cannabis Stock News: TILT Holdings (NEO: TILT) (OTC: TLLTF), Shinnecock Nation and PowerFund Partners Finalize Change in Partnership of Little Beach Harvest Joint Venture

Cannabis Stock News: TILT Holdings (NEO: TILT) (OTC: TLLTF), Shinnecock Nation and PowerFund Partners Finalize Change in Partnership of Little Beach Harvest Joint Venture: Cannabis Stock News: TILT Holdings (NEO: TILT) (OTC: TLLTF), Shinnecock Nation and PowerFund Partners Finalize Change in Partnership of Little Beach Harvest Joint Venture

Cannabis Stock News: MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) Completes Sale of Vacant Land for Cash Proceeds of $1.9 million

Cannabis Stock News: MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) Completes Sale of Vacant Land for Cash Proceeds of $1.9 million: Cannabis Stock News: MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) Completes Sale of Vacant Land for Cash Proceeds of $1.9 million

Cannabis Stock News: Curaleaf (CSE: CURA) (OTCQX: CURLF) Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables

Cannabis Stock News: Curaleaf (CSE: CURA) (OTCQX: CURLF) Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables: Cannabis Stock News: Curaleaf (CSE: CURA) (OTCQX: CURLF) Expands Brand Portfolio With Launch of Zero Proof ™ Cannabis-Infused Drinkables

Friday, September 1, 2023

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move: (OTC: $PSYC), (OTCQB: $DBCCF), (OTCQB: $INNPF), (OTCQB: $MEDIF) and (NASDAQ: $CGC)

 



 

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move: (OTC: $PSYC), (OTCQB: $DBCCF), (OTCQB: $INNPF), (OTCQB: $MEDIF) and (NASDAQ: $CGC)

 

September 1, 2023 (Investorideas.com Newswire), investorideas.com,  a global news source covering leading sectors including marijuana and hemp stocks and its potcast site  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2023/090123-Cannabis.mp3

 

Read this in full at https://www.investorideas.com/news/2023/cannabis-potcasts/09011PSYC-DBCCF-INNPF-MEDIF-CGC.asp

 

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

 

Today’s podcast overview/transcript:

 

In today’s podcast we go over a few public company announcements, the potential for cannabis rescheduling in the U.S. as well as a frank discussion on cannabis studies and drug studies in general.

 

PSYC Corporation (OTC: PSYC), parent company to Spotlight Media Corporation, announced the Company, through its wholly owned subsidiary, Spotlight Media Corporation, has completed the acquisition of the Stock Day Media platform from La Jolla Media, LLC.

 

The deal, which is effective September 1, 2023, is valued at $500K and will be satisfied by the Company through a combination of cash and stock distributions over the course of the next 12 months and contingent upon the achievement of specific net revenue targets mutually established between the Company and Stock Day Media.

 

The acquisition follows the formation of a strategic partnership between the Company and Target Media that was announced on August 29, 2023 and which, according to the Company, played a strategic role in providing the Company with the initial financing required to execute this acquisition.

 

Founded in 2013, Stock Day Media has become one of the fastest growing media outlets for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day Media provides companies with customised solutions to their news distribution in both national and international media outlets.

 

The Stock Day Media website contains over 500 hours of resourceful digital content that includes approximately 1,500 podcast episodes published to Audioboom and an estimated 2,000 podcast episodes published to its website.

 

The Company believes there may be an opportunity to leverage the respective service offerings and brand authorities provided by Stock Day Media along with its existing investor awareness-focused platforms such as Technical 420, On the Bids, and Mushroom Stocks to increase its market share within the investor awareness and public relations sectors and to develop this arm of its business operations into a more prominent revenue driver for PSYC.

 

“We are at a stage in the evolution of PSYC where monetizing our assets and developing a solid and steady revenue model that is pragmatically capable of contributing to our objective of reconstructing our balance sheet is of paramount importance,” said PSYC CEO, David Flores.

 

“Over the past 3 plus years, I have had the privilege of working with Everett Jolly and the amazing Stock Day Media team and have witnessed firsthand the incredible value their platform can deliver to companies in the public arena. I believe that integrating their platform beneath the evolving PSYC umbrella of multimedia assets represents a huge opportunity for the Company’s current and future value proposition. As highlighted in our press release earlier this week (PSYC Enters Strategic Partnership with Target Media to Help Accelerate Audience and Revenue Growth Opportunities), the Company has increased its year-over-year revenue earnings by nearly 94%. This has primarily been a result of our acquisition of Technical 420 and On the Bids last September which are platforms geared towards servicing companies in the public markets. With Stock Day Media being a platform that is currently producing sales-related revenue, we can reasonably anticipate for it to have an immediate and positive impact on our bottom line right out of the gate and hopefully build on this revenue growth in the months ahead. Additionally, the board and I are also confident that we have structured this acquisition prudently and in a manner that we believe is friendly and advantageous to our shareholders and our ongoing operations budget by minimizing, to the extent possible, dilution, as well as preserving our cash-on-hand by ensuring that future cash payments are tied directly to the achievement of specific net revenue-related milestones.We would also like to thank our new partners at Target Media who played an instrumental role in helping to make this acquisition possible through a strategic loan financing agreement that they made available to the Company earlier this month.

This, in my opinion, is a clear example of the tremendous value the Target Media team is actively delivering to PSYC and how they are committed to working with us on helping to place the Company on viable a path to becoming a formidable multimedia powerhouse.”

Stock Day Media Founder and CEO, Everett Joly, shared his thoughts on joining the PSYC team: “Stock Day Media is excited about the opportunity to join PSYC Corporation who has been a long-standing client and recurring guest on our show over the past several years.

In the last few years alone, Mr. Flores and his team have made wonderful progress with developing PSYC Corp into a leading media authority for the psychedelics and cannabis sectors. And I believe that by bringing our Stock Day Media platform into their business model, we are helping to build off of this progress and are helping to create a more dynamic and results-driven model that will ultimately contribute to and enhance the monetization capabilities of every platform under their umbrella. I am also looking forward to the opportunity that I believe this will present for us to expand Stock Day Media’s existing business model and to focus on growth-related strategies designed and intended for us to capture a larger and more significant market share in the months ahead.”

 

Decibel Cannabis Company Inc. (TSXV: DB) (OTCQB: DBCCF), announced that it has expanded its global footprint by entering into a supply agreement to provide premium dried medical cannabis flower to 4C LABS, a healthcare, technology, and pharmaceutical company focused on virtual prescribing, pharmaceutical distribution and clinical development in cannabis based medicinal products for human health in the United Kingdom and Channel Islands (the "UK").

 

Key Highlights

       Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients

       Decibel to grant strain exclusivity of rare and unique cultivars to be distributed by 4C LABS

       3-year supply agreement

       Initial shipment expected before year end

       Minimum purchase commitments achieve exclusivity over certain genetics and QWEST brand in the UK

 

"We are excited to partner with 4C LABS, a leading organization in the growing medical cannabis industry in the UK, that echoes Decibel's commitment to quality and patient care. Not only will this unlock a strong partnership and a new market for Decibel's craft cannabis products, it also sets the stage for further growth into other European markets," said Adam Coates, Chief Revenue Officer. "Decibel's success with Qwest flower products in Canada and in Israel's medical market reinforces the demand for premium cannabis products and the reputation we have built to service that demand."

 

"4C LABS is building a patient focused best-in-class product line for the UK & Channel Islands, the Qwest craft flower line strengthens the top end of the 4C LABS product offerings. Decibel's innovative craft quality Qwest flower products will fill an empty segment in the UK market and bring a world class BC Cannabis product to UK patients," said Greg Dobbin, CEO 4C LABS. "Decibel's success in Canada, the most competitive cannabis market in the world, is a product of hard work, innovation and attention to detail, qualities that will resonate with UK patients."

 

Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPFannounced the results of a clinical study regarding the pain-relieving effects and safety of the Company's subcutaneous liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine". The Study highlights that CBD plasma levels were detected for six weeks following a single subcutaneous dose of Liposomal-CBD, causing minimal side effects and effectively decreasing pain, leading to improved well-being in affected dogs.

 

In the study, six dogs with naturally-occurring osteoarthritis, unresponsive to conventional medications, were treated with a single injection of five mg/kg liposomal-CBD (in addition to their routine medications). The subsequent observations spanned six weeks and included measuring CBD plasma concentrations, blood work, collar activity data, and evaluations of well-being and pain. The results were encouraging; dogs exhibited a substantial drop in pain levels and an uptick in activity.

 

Key findings include:

       Prolonged CBD detection in the plasma with a peak concentration of 45.2 (17.8-72.5) ng/mL.

       Significant decrease in pain and increase in well-being for several weeks.

       Significant increase in activity (objectively measured) by the fifth and sixth weeks.

       Minor swelling at the injection site in five out of six dogs, which resolved within a few days without any treatment.

 

The study underscores the effectiveness and increased bioavailability of LPT-CBD tested as part of a multimodal pain management in dogs with osteoarthritis. With the drug's plasma concentrations detectable for six weeks and high exposure in terms of AUC (area under the concentration-time curve), the research suggests that this liposomal formulation could become a useful addition to pain management strategies for improving the quality of life in dogs with osteoarthritis.

 

Read the full study on Frontiers in Veterinary Science:
Frontiers | Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis (frontiersin.org)

 

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIFannounced that Harvest Medicine's study entitled, "Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series" has been published in the peer-reviewed American Journal of Endocannabinoid Medicine. Harvest Medicine Inc. ("Harvest Medicine" or "HMED") includes a medical clinic network, and is a wholly owned subsidiary of MediPharm Labs.

 

The retrospective study was led by HMED and reviewed data from 805 patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and had a minimum of one follow-up assessment. The majority of patients (76.1%) reported using CBD oil, which aligns with the current practice guidelines for authorising medical cannabis as an adjuvant therapy for managing chronic pain.

 

The primary findings from the present study include  a significant reduction in all three scores measuring depression, anxiety, and illness severity between baseline and first follow-up.

       75% of patients saw a decrease in their self-reported illness severity, which may include chronic pain, insomnia, and fatigue.

       Anxiety scores were improved in 22% of those patients reporting mild-moderate severity, and in 48% of patients reporting severe anxiety.

       27% of patients reporting mild-medium depression noted a reduction in symptoms, while 48% of patients reporting severe depression showed a reduction in PHQ-9 score.

 

The validated study data shows that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety, and that additional, similar studies are recommended.

 

"Since 2017, Harvest Medicine's primary objective is to improve the quality of patients' lives by providing access to medical cannabis and offering the highest standard of medical care with a scientifically informed approach" commented Barbara Vermeulen, Director of Harvest Medicine. "We will continue to advocate for patients to maintain access to physician guided consultations and education, with the goal of reducing stigma among health care professionals and advancing patient outcomes".

 

Details on the study can be viewed on American Journal of Endocannabinoids Website.

 

In other recent news reported by Marijuana Moment, earlier this week the U.S. Department of Health and Human Services (HHS) officially recommended that cannabis be moved from Schedule I to Schedule III under federal law—a historic development that means the top health agency no longer considers cannabis to be a drug with high abuse potential and no medical value.

After completing a scientific review into cannabis under a directive from President Joe Biden last year, HHS is now telling the Drug Enforcement Administration (DEA) that it believes cannabis should be placed in Schedule III of the Controlled Substances Act (CSA). The recommendation is not binding, and DEA has the final say, but the scientific analysis combined with growing political support for cannabis reform may well influence DEA to make the change.

 

“Following the data and science, HHS has expeditiously responded to President Biden’s directive to HHS Secretary Becerra and provided its scheduling recommendation for marijuana to the DEA on August 29, 2023,” an HHS spokesperson said in a statement to Marijuana Moment on Wednesday. “This administrative process was completed in less than 11 months, reflecting this department’s collaboration and leadership to ensure that a comprehensive scientific evaluation be completed and shared expeditiously.”

 

Moving cannabis to Schedule III would also unlock marijuana industry tax opportunities that are currently unavailable.

 

Following this announcement, U.S. Senate leaders hailed the recommendation Wednesday as a first step toward easing federal restrictions on cannabis.

 

Shares in Canopy Growth Corp. (NASDAQ:CGC) rose more than 28 per cent Thursday, after climbing nine per cent Wednesday. Tilray Brands, Inc.(NASDAQ:TLRY) shares also saw a rise, almost 11 per cent, after its stock rose more than 10 per cent Wednesday, and shares of Aurora Cannabis Inc. (NASDAQ:ACB) rose almost five per cent.

 

While this is optimistic news at the moment for the cannabis sector, there is one issue when it comes to cannabis as well as drug studies in general in the current medical and corporate world; almost all of them are biassed and therefore unreliable.

 

I wouldn’t go as far as to say there is falsified data in any of either the pro or anti cannabis studies that circulate the web on a weekly basis, but the issue is, oppositional studies exist alongside one another at all times.

 

This week alone I saw several articles discussing studies showing that cannabis use is leading to an increase in schizophrenia and cannabis use disorder, while at the same I saw articles come out claiming the opposite.

 

Below are links to a few examples to get an idea of what I’m talking about.

 

How marijuana impacts pain, sleep, anxiety and more, according to the latest science | CNN

 

Young people, pregnant women and drivers should avoid cannabis – study | Cannabis | The Guardian

 

Study: Young MJ Consumers With Psychosis Risk Saw Symptom Improvement | High Times

 

Is smoking cannabis actually healthier than smoking tobacco? – study - The Jerusalem Post (jpost.com)

 

UM Today | Rady Faculty of Health Sciences | Are cannabis products safe and effective for reducing symptoms in children with cancer? (umanitoba.ca)

 

The issue is, both studies seem reliable at first glance, but upon further scrutiny, both sides of the argument prove to be biassed.

 

The issue stems from corporate owned “medical journals”.

 

Certain Pharmaceutical companies own different medical journals to add legitimacy to their products, and this is a well known fact in the world of medicine and drug development. As cannabis continues to expand its reach the same is now true for the cannabis industry.

 

There are still seemingly reputable sources such as Johns Hopkins, but even they have produced opposing studies and findings.

 

Even anecdotal evidence is hard to take into account as the internet has become ripe with false accounts, false information and opposing narratives.

 

What seems to be close to the truth is that cannabis is a serious competitor to traditional pharmaceuticals on the market, whether we are looking at pain management drugs, anxiety or depression drugs or cancer drugs. What also seems true is that the cannabis industry and research in general regarding micro-cannabinoids is still in its infancy compared to other substances currently available through the traditional pharma/medical model.

 

The problem with cannabis and opposing studies is the same problem we see for nearly all medicine on the market today. I don’t even want to get started on vaccines.

 

So moving forward, especially as we see the pharmaceutical industry begin to hedge their bets and invest in synthetic cannabinoids, which are a nightmare and should be tossed aside, how does cannabis avoid going down the same path of every other medical product on the market today?

 

No one wants to see side effect warnings for cannabis catch up to pharmaceuticals in 5 years, but based on the current trajectory of things, that isn’t outside the realm of possibility,

 

So while I do still believe overall in the benefits of cannabis, mainly due to my lived experience and interactions with hundreds of people who have explained their stories of how cannabis use massively improved their quality of life and overall health, it is hard not to look at how business is slowly infecting cannabis with all the mistakes of the past.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) ,  Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio ,  Google Podcasts and most audio platforms available.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders.  Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast ,  Cleantech and Climate Change Podcast,  Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast.  We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water.

Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.